Business Context and Reporting Period
This Form 8-K filing by Bionano Genomics, Inc. (BNGO) reports a significant capital raising event. The report date is October 21, 2019, with the offering closing on October 23, 2019. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing details a public offering rather than periodic financial performance metrics such as revenue or operating profit.
- Gross Proceeds: Approximately $18.0 million.
- Securities Issued: 10,013,600 shares of common stock and pre-funded warrants to purchase 10,923,958 shares.
- Warrants Issued: Common warrants to purchase up to 20,937,558 shares.
- Offering Price: $0.86 per share of common stock (with accompanying warrant); $0.859 per pre-funded warrant (with accompanying warrant).
- Warrant Terms: Common warrants are exercisable at $0.86 per share and expire five years from issuance. Pre-funded warrants are immediately exercisable at $0.001 per share.
Material Changes
The primary material change is the expansion of the Company's capital base through the issuance of equity and warrant securities. The filing does not provide comparative financial data against prior periods as it is a current event report.
Guidance, Outlook, and Risks
Use of Proceeds: The Company anticipates using net proceeds for general corporate purposes, including working capital, sales and marketing activities, general and administrative matters, and capital expenditures.
Risks and Forward-Looking Statements: The filing includes standard forward-looking statements regarding the anticipated use of proceeds. Actual results may differ due to risks associated with the Company's business and financial condition, as detailed in its Annual Report on Form 10-K for the year ended December 31, 2018.
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting discounts and offering expenses.
- Confirm the dilution impact of the 20,937,558 common warrants and 10,923,958 pre-funded warrants on existing shareholders.
- Review the Company's cash burn rate to assess the runway provided by the $18.0 million gross proceeds.
- Check subsequent filings for the actual allocation of funds between working capital and capital expenditures.